U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636252) titled 'EX VIVO DRUG RESPONSE PROFILING AND OUTCOME PREDICTION IN LUNG ADENOCARCINOMA' on June 04.
Brief Summary: This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
Study Start Date: June 14, 2023
Study Type: OBSERVATIONAL
Condition:
Lung Adenocarcinoma
Malignant Pleural Effusions (Mpe)
Intervention:
OTHER: Non-Interventional Study
Non-Interventional Study, patients go through pleural drainage due to shortness of breath
Recruitment Status: RECRUITING
Sponsor: Sheba Medical Center
Publish...